Status:

COMPLETED

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome

Lead Sponsor:

Novartis

Conditions:

Hypertension, Dyslypidaemia

Eligibility:

All Genders

40-65 years

Phase:

PHASE4

Brief Summary

This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome.

Eligibility Criteria

Inclusion

  • Age between 40 - 65 years
  • Diagnosed metabolic syndrome
  • Risk of cardiovascular death ≥ 5% (according to SCORE)
  • Written informed consent

Exclusion

  • Women not in menopause or not using efficient contraception
  • Known hypersensitivity to study drugs
  • History of ischemic heart disease

Key Trial Info

Start Date :

July 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

144 Patients enrolled

Trial Details

Trial ID

NCT00821574

Start Date

July 1 2005

End Date

March 1 2007

Last Update

March 1 2017

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome | DecenTrialz